Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs iShares TIPS Bond ETF (TIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs iShares TIPS Bond ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while iShares TIPS Bond ETF trades at $105.3 (market cap $14.33B). The key difference: iShares TIPS Bond ETF is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and iShares TIPS Bond ETF for 64 Days on average.
| SYRE | TIP | |
|---|---|---|
Market Cap | $7.52B | $14.33B |
Volume | 1,441,031 | 1,485,284 |
Sector | Health | Fixed Income |
52-Week High | $108.92 | $112.20 |
52-Week Low | $22.18 | $103.98 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
TIP trades at $104.56 with minimal daily movement (+0.06%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The ETF shows limited price volatility with support at $104 and resistance at $105. Recent institutional activity includes Envestnet Asset Management increasing its stake by 3.5% in the latest quarter.
The ETF faces headwinds from rising Treasury yields and bond market volatility, though its inflation-protected structure provides defensive characteristics. Key risks include continued bond market selloffs and geopolitical tensions affecting oil prices. The upcoming dividend payment of $0.78 scheduled for August 2026 offers income stability amid market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →
